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Objtthvtt. The Total lschemic Burden Bisoprolol Study 
(TIBBS) Pollow-up examined cardiac event rates in relation to 
traasltnt ischemla and its treatment. 
&&round. It is unclear whether transient iscbemia on the 
ambulatory electrocardiogram has prognostic implications in 
stable angina and whether medical trenlment can improve the 
&WOgIlOSiS. 
h&hods. The TlBBS trial was an 8.week, randomized. con- 
trolled ntmparison of the effects of bisoprolol and nifedipine on 
transient iscbemic episodes in patients with stable angina pecto- 
ris. Of the 545 patients screened, 520 (95.4%) could be followed 
up. Baks of cardiac and noncardiac de&b, nonfatal acute myo- 
CUNBUI infarction, hospital admission for unstable angina and 
need for coronary artery bypass graft surgery or percutaneous 
rransbimiaal coronaq angioplasty were mcorded. 
lfemlts. A total of 145 events ~curred in 120 (23.1%) of 520 
patients. Patients with more than six episodes bad an event rate of 
325% cumpand with 25.0% for pi&&r with hvu tu six episodes 
ll_l- -__---_ ___ - 
In different subsets of patients with coronary artery disease, 
prognostic significance has heen demonstrated for transient 
ischemic episodes dctcctcd by ambulatory monitoring. 
The highest corrckttion of transient ischcmia with a&se- 
quent higher evcnl rales was found for patients with unstable 
angina pcctoris (I-Y): howcvcr, patients who have had an acute 
myocardial infarction (l&-14) and patients with stable angina 
pectoris (15-19) have also been shown to have increased event 
rates when transient. predominantly silent &hernia is present 
on ambulatory electrocardiographic (ECG) monitoring. In 
stable angina pcctoria. the practical WIUC of the ambulalory 
EW for the dctcction ot ischemia has been a mal(cr oftlispule 
(30-23). hut recently published trials ahon+ an improved om- 
come ilflcr respc.iisc lo lreatmenl (24.75). 
The Total lvchemic Burden Risoprolol Study (TIBBS) (2h) 
- 
and 13.2% for patients with less than two episodes (p < 0.001). 
Ilard events (death, acute myocardial infarction, hospital admis- 
sion for unstable angina pectorls) were more frequent in paBents 
with two or more isehemic episodes (12X6 vs. 4.7%, p = 0.0049). 
Patients with a IO@% response rate of transient ischemic episodes 
during the TIBBS trial bad a 17.5% event rate at I year compared 
with 32.3% for non-100% responders (p = 0.008). Patients receiv- 
ing bisopmlol during the TIBBS trial had a lower event rate 
(22.1%) a1 I year than patients randomized to nifedipine (33.I%, 
p = 0.033). 
Conclusions. In patients with stable angina pectoris, kequeat 
episodes of transient iscbemia are a marker for an increased event 
rate. A 100% response to medical treatment reduces the event 
rate. Tbe greater reduction of iscbemia with bisopmlol than 
nifedipine during the TIBBS trial translated into an improved 
outcome at 1 year. 
(J Am Coil Car&l 1996:28:20-4) 
was designed to compare the Ma,-selective blocking agent 
bisoprolol with the calcium channel blocking agent nifedipine, 
which were used to treat transient ischemia in a large patient 
group. Both drbgh reduced the m&er of is;hemic episodes, 
hut hi\oprdol proved to be significdy more effective. The 
follow-up study aimed to answer %vo questions: 1) Is a 
prognostic influence of transient &hernia demonstrable at I 
year; and 2) does the etTect of medical treatment in reducing 
ischemia translalc into an improved prognosis’? 
Methods 
Initial study design. The follow-up to TIBBS was an 
obsc:vational study aimed at prognostic comparison in well- 
dciincd croups of TIBBS patient\ with stahlc angina pcctoris 
and a positive exercise EW. The design and rc!,ulta of TIHBS 
have been publi~hctl in d&ii III Ihi* journal (26). In short, it 
W<IS a randomihcd. doublc~blind. controlled. parallel group 
trial of hi\oprohll (4 weeks at 10 mg once daily, followed hy 4 
W&S at 20 mg once daily) versus slew-release nifedipine (20 
rnp lwicc daily). It included patients with stable angina pecto- 
ris. positi\c exercise ECii results and Iwo or more transient 
ischcmic cpisodcs on the 48-h ambulatory ECG. Bolh !reat- 
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Table 1. TIBBS Fc~llow-Up: Number of Events (one or more event/patient) 
Cardirc NWlCAfdiX 
Death Death MI 
Hospilal Admission 
for Unstable 
Angina CABG I’IIZA 
All paticnls (n = 520) 4 2 I? 35 72 2u 
Only 1 (SevcrcS) evem/patient 4 ? 11 32 55 16 
lschemic episodes at baseline 
<2 (n = Ml) n n 2 6 13 5 
2-6 (n = 164) ‘) I 3 19 2.3 5 
>6 (n = 166) n 0 7 III .36 IO 
Responders 
IHn? (a = 97) I 0 I 6 in 3 
NwI-llnY% (II - llifl) I I 3 16 42 8 
fiiwpndol (n = ISJ) I 0 2 IO 22 5 
Nikdipine (slow release) I) 2 7 16 36 7 
(n = 163) 
.-- 
CABG = coronary artery bypass graft surgery; Ml = mycxardial inhr~?ion; PICA = pcrcutanrous translumuz; 
coronary angiopiasy: TIBMS -: Tokd khemic Hurden Biwpr&l Study. 
ments greatly reduced the number of transient ischemic epi- 
sodes, but bisoprolol was significantly more effective (e.g., 
10 mg of bisoprolol reduced the number of transient ischemic 
episodes from a mean of 8.1 [SEMI i: 0.56 at 48 h to 3.2 -i: 
0.41, vs. nifedipine, 2 x 20 mg, from 8.3 + 0.5 to 5.9 t 0.43. 
p < 0.001). The randomized treatment phase of the study was 
completed in 8 weeks. After that, the patients’ symptoms were 
treated at the discretion of their physicians, to whom the 
results of the ambulatory monitoring during treatment were 
not disclosed. 
Follow-up. At 6 months and 1 year from the randomiza- 
tion, screened patients underwent follow-up examinations. 
Patients who were screened on the basis of a history of stable 
angina and a positive exercise ECG but who did not show two 
or more transient ischemic episodes. as well as those who 
showed transient &hernia and had been randomized to con- 
trolled treatment in TIBBS, were followed up. 
Patients were excluded from follow-up if their 48-h Holter 
tapes were not technically acceptable during the placebo 
prephase of TIRES. In all 30~~articip~tingcenten, the patients 
were monitored by repeated visits, telephone calls or inter- 
views with their treating physicians. Information was obtained 
as to whether the patients had had any of the following events: 
I) cardiac death. 2) noncardiac death. 3) nonfatal myocardiai 
Infarction, 4) admission to the hospital owing to unstable 
angina, 5) the need for percutaneous transluminal coronary 
angioplasty or 6) coronary artcry bypass graft surgery. Events I 
through 4,sccre evaluated together with the other events and 
separately 11s “hard events” because they do not have the bias 
problem of an elective treatment decision. The definition of 
nonfatal actite myocardial infant ion followed standard critc- 
ria. Indications for admission trwin!! to unstable angina and for 
revdsculariz.ttion were at the discretion of the physicians in 
charge of the patients in the different centers. These physicians 
were unaware of the results of the initial ambu!atory ECG 
monitoring and the treatment assignment. Furthermore, pa- 
tients were asked about the antianginal medication they had 
taken from the randomized treatment phase up to I year. 
On the basis of history and positive exercise ECG results, 
630 patients were included in the screening phase of TIBBS 
and underwent 48-h Holter monitoring. Of these patients, 85 
had no or technically unacceptable Halter tapes during the 
placebo prephase and were excluded. Follow-up information 
was not available for 25 patients, thus giving a follow-up rate of 
95.4%. Of the 520 patients evaluated for follovr-up informa- 
tion, 203 were screened only by Halter ECG but not random- 
ized, and 317 entered the randomized treatment phase of 
TlBBS. Of the latter group, a subgroup of 283 patients showed 
valid 48-h Halter tapes also during the IIBBS randomized 
treatment phase, and thus could be evaluated for treatment 
responses of transient ischemia. 
Statistical analysis. All data from the follow-up report 
forms were continuously entered into a central data base. This 
allowed cross-correlations with information obtained on the 
same patients during GIBBS. 
For comparisons of proportions of patients with events, the 
Fisher exact test or chi-square test was used, and the log-rank 
test was used for comparisons of event-free survival curves. 
The occurrence of events in the time court was described by 
life-table curves (Kaplan-Me&). Significance level was alpha 
5% (hvo-Failed). 
Results 
Eveat rates. Table I shows the number of patients with 
evrnts that occurred in our patient group. Of the 520 patients 
at risk, 120 had a total of 145 events. If only the severest event 
per patirm was cuuntcd, tlic rvwl rdte w* Z3. I% (l2Oof 520). 
with Y.l% (4Y of 520) hard events (death, acute myocardial 
infarction, hospital admission owing to unstable angina). 
Medical treatment at 6 months of follow-up included 
platelet aggregation inhibitors (59.4%). beta-blockers (59.4%), 
long-acting nitrates (57.2%), short-acting nitrates (48.9%). 
calcium antagonists (47.8%). angiotensin-converting enzyme 
inhibitors (7.6%) and anticoagulants (7.0%). Beta-blockers 
were used exclusively (without calcium antagonists) in 37.3% 
22 “ON ARNIM JACC Vol. 28. No. I 
PROGNOSTJC INFLUENCE OF TRANSIENT ISC‘HEMIA July 19QMil -4 
0.5 0.5 
bg rank feet pco.001 
t 
I loo 1502002503003504000ay 
c, I I I I I # I 
tog- mnktes, p-O.015 
0 Jo 0 50 loo 150 2w 250 300 350 400 Daya 
F@n-e 1. Event-free survival to first evcnl in 520 patients screened for Figure 3. Event-free survival in 283 patients treated in the random- 
the Total lshemic burden Bisoprolol Study. One hundred ninety ized. controlled phavc of the Total lschrmic Burden Bisopmloi Study 
patients showed less than two transient ischemic episodes on 48-h (only patients who had technically acceptable tapes throughout the 
ambulatory electrocardiographic monitoring: 164 patients had two to g-week t&t). A 100% reduction of transient ischemic episodes was 
six episodes; and 166 patients had more than six episodes. A higher achieved in 97 patienls who had a reduced risk of subsequent events 
number of episodes is clearly followed by an increased event rate. over non-100% responders (I86 patients). 
of patients, calcium antagonists exclusively (without beta- 
blockers) in 27.9% and a combination of both in 19.8%. At 1 
year of follow-up, there were no significant changes in the 
frequencies of the dttferent medications used. 
Prognostic influence of transient ishernia. Of the 190 
patients with less than two ischemic episodes, 13.2% had an 
event, compared with 25% of the 164 patients with two to six 
episodes and 32.5% of the 166 patients with more than six 
episodes (chi-square, p < 0.001). Hard events occurred in 
4.7%, 14.0% and 10.2% of those with less than two ischemic 
episodes, two to six episodes and more than six episodes, 
respectively (p = 0.01 I). Figure I shows the event-free survival 
for patients grouped according to the number of transient 
ischemic episodes on the 48-h Holter ECG during the placebo 
prephase of the TIBBS trial. There is a clear stepwise separa- 
tion of the event-free probability curves between patients with 
less than two cpisodcs and the other two groups with more 
sevcrc ischcmia. 
In Figure 2 only hard events were counted for patients 
separated into two groups, those with less than two transient 
Figure 2. Event-free s&val for hard events only (death, acute 
myocardial infarction, hospital admission for unstable angina) in 
patients screened for the TomI Ischemic Burden Bisoprolol Stu& 
Two or more episodes (Ml patients) confer a significantly increauo 
risk at I year over patirrm with less than two episodes (I90 patients), 
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ischemic episodes and those with two or more episodes. Again, 
there is a significant separation at 1 year, demonstrating the 
prognostic influence of transient &hernia. When the total 
ischemic burden and the duration of ischemic episodes are 
taken as measures of ischemia and the two groups are sepa- 
rated, respectively, on both sides of the median, then the event 
rates are also significantly higher in the groups with a higher 
total isehemic burden and a longer duration of ischemia. 
Pmpostk influence of response to treatment. Patients 
who showed a 100% reduction of their transient ischemic 
episodes under treatment had an event rate of 17.5%, com- 
pared with a 32.3% event rate in non-100% responders (p = 
O.OM). Hard events were 7.2% and 11.3% in 100% and 
non-MO% responders, respectively (p = 0.276). Figure 3 shows 
the event-free survival curves for patients with or without a 
100% response to medical treatment, i.e., no transient isch- 
emit episodes on the control Holter tapes (week 4 or 8 of 
randomized treatment) during GIBBS. Patients who had a 
complete response and who lost all transient ischemia had a 
significantly improved outcome compared with the rest of the 
randomized patients. When only hard events were counted, the 
separation was not statistically significant (log-rank test, p = 
0.258). Treatment responses with a <lOO% reduction of 
ischemic episodes did not show an improved prognosis. In fact, 
the event rates for patients with at least a 25% reduction 
(26.l%), at least a 50% reduction (24.7%) and at least a 75% 
reduction (24.3%) were simtlar and different from patients 
with a loft% reduction (17.5%). 
Prognostk lnllaence i# Initial ~a&mized treatment. Pa- 
ticnts randomized to receive bisoprolol had an event rate of 
‘!?.I%, compared with 33.1% in the patients receiving niiedi- 
pine (Fisher exact test. p = 0.033). Figure 4 compares the 
event-free survival curves for patients randomized to receive 
either hisoprolol or nifedipine during the initial randomized 
treatment phase (X weeks). Patients who had been given 
bisoprolal during TlBBS fared significantly better than those 
who had been taking nifedipine. Even when onfy the hard 
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Mgttre 4. Event-free survival for 317 patients treated in the random- 
ized, controlled phase of the Total Ischemic Burden Bisoprolol Study. 
The patients who had received blprolol (n = 154) during the trial 
had a signhlcantly lower event rate than patients who had received 
slow release (s.1.) nifedipine (n = 163). 
events were counted, a trend remained (log-rank test, p = 
0.104). 
Patients randomized to receive bisoprolol during the initial 
phase of the study were kept on beta-blockers by their physi- 
cians more often than patients randomized to receive nifedi- 
pine (47% vs. 32%, p = 0.008). Treatment with calcium 
antagonists during follow-up was comparable for hoth groups 
(21% vs. 26%, p = 0.29). 
Discussion 
Influence of patient selection. The present study followed 
patients who had undergone a screening phase for a random 
ized, controlled treatment study. Thus it could compare pa- 
tients who had shown episodes t.i transient &hernia to others 
who had not. It has to be noted that all patients had a history 
of stable angina pectoris and positive exercise ECG results. 
Thus, the results pertain especially to the additive prognostic 
influence of transient ischemic episodes on ambulatory 48-h 
monitoring. The follow-up rate at 1 year was >9.5%, and thus 
the results validate Earlier studies showing prognostic signill- 
cance for transient, predominantly silent &hernia in patients 
with stable angina pcctoris (15-19). Our study group was Large 
enough to show a significant prognostic separation also for 
hard events. 
Gur results underscore the prognostic importance of tran- 
sient ischemia. if demonstrated additively to a positive ‘:xercise 
ECG. Transient ixhemic episodes may represent a $n of 
underlying instability of the disease in patients who otherwise 
present with stable angina pectoris. In the study of Mulcahy et 
al. (20), a positive exercise ECG was not a prerequisite for 
inclusion of the patients, and this “dilution” of the patient 
group may be the reason for the lack of prognostic implications 
in their study. We would, however, think that the prognostic 
intluence of transient ischemia that we have shown is not onIy 
stati&caUy significant but also clinicaUy relevant. 
Pmgno&c Mncnce of lrentmmt F The follow-up 
of patients who had tmdergone the mndomii treatment 
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phase of TIBBS showed a remarkable effect of treatment 
response on prognosis. Although the treatment was not ran- 
domized over 1 year, but only for the 8 weeks of the trial, the 
results are valid, as the r’ .~tts of the ambulatory monitoring 
during the trial were not disclosed to the physicians in charge 
of the patients during following year. The present study is, of 
course, observational in tbii ‘respect, but treatment responses 
on ambulatoty ECGs were measured during the controIIed, 
randomized phase of the study. The effect of initial treatment 
could ooIy have been dihtted during foIIow-up, especiahy for 
hard events. Our study shows that a complete treatment 
response confers an improved prognosis for the patier@ even 
over 1 year. It is important that the response of ischemia be 
lOO%, because lesser reductions of episodes were not associ- 
ated with improved prognosis. Our results compare very weII 
with the recently published Atenolol Silent Irhemia Study 
(ASlST) trial (24). In this study patients underwent random- 
ized treatment *rith atenolol or placebo, and a beta-blocker 
also reduced the amount of &hernia and improved prognosis. 
As in our study, complete relief of ischemia under medical 
treatment was important for a positive inlhtence on prognosis. 
In regard to the marked effect, which the treatment response 
during the &week trial had for the outcome at 1 year, the 
recent report of Gill et al. (27) is interesting in their compar- 
ison of 406 patients who had an acute myocardial infarction: 
those with ischemia on the ambulatory ECG had a highly 
increased event rate, the difference occurring aImost com- 
pletely during the first 3 months. Pepine (28) pointed out the 
possibility of biologically unstable coronary artery disease in a 
clinically stable patient, 
DiPerences between trenhnents. In our study the positive 
treatment effects shown by bisoprolol during the randomized 
phase of the trial (26) translated into improved outcomes at 1 
year. This seems difficult to explain at first, but the initial 
stabilization of some degree of instability may be one reason. 
Another important factor may be that the patients who had 
beer, ndomized to bisoprolol treatment were significantly 
more ..cly to be kept on beta-blockers for the following year. 
Thus, the higher rate of complete treatment responses ob- 
tained with bisoprolol may have bad an extended effect on 
subsequent prognosis. With the higher dose of 20 mg of 
bisoprolol a lOO% response of ischemic episodes was achieved 
in 52% of the patients (26). Thus. a sizable proportion of 
patients who are probably not treated to an optimal outcome 
remains. Further studies will have to address the question of 
whether the percentage of complete treatment responses can 
be improved by combination therapy of a beta-blocker like 
bisoprolol with a calcium antagonist (29.30). aggressive lipid- 
lowering therapy (31) or a strategy including revascularization 
(25.3233). The recently published Asymptomatic Cardiac 
Ischemia Pilot (ACIP) trial (253533) showed revarctdlariza- 
tion to be somewhat superior to medical treatment in the 
reduction of subsequent cardiac events. 
Cor&na&w& The l-year follow-up of patients with stable 
qngina pectoris, but demonstrable frequent transient &hernia 
;n addition to positive exercise ECG rest&s, showed a signifi- 
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cantly worse prognosis than patients with less or no transient 
ischemia. This tinding may represent a degree of hidden 
instability of the coronary artery disease in such patients. 
Medical ircatment can im&uvc the prognosis if it achieves a 
100% reduction of ischemic episodes. Patients taking hisopro- 
lol during the GIBBS trial fared better than those initially 
randomized to receive nifedipine, probably because patients 
taking bisoprolol had a higher rate of 100% responses. 
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